CD274 and non-small cell lung carcinoma: In addition, a pooled analysis of nivolumab in patients with previously treated NSCLC with <1% PD-L1 expression revealed a four-year OS of 11% [12]; a five-year update of pembrolizumab in patients with previously treated NSCLC with 1–49% PD-L1 expression showed a four-year OS of 9.2% [21], both supporting sequential treatment.